

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Fungiconazol 400 mg tablets for dogs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains:

**Active substance:**

Ketoconazole 400 mg

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>
Microcrystalline cellulose
Sodium starch glycolate, type A
Sodium laurilsulfate
Dried yeast
Chicken flavour
Colloidal anhydrous silica
Magnesium stearate

Brown spiked, round flavoured tablets, quadrisect.  
The tablets can be divided into halves and quarters.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Dogs.

#### **3.2 Indications for use for each target species**

Treatment of dermatomycoses due to the following dermatophytes:

- *Microsporum canis*,
- *Microsporum gypseum*,
- *Trichophyton mentagrophytes*.

#### **3.3 Contraindications**

Do not use in animals with liver failure.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 3.4 Special warnings

Although rare, repeated use of ketoconazole may induce cross-resistance to other azoles.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level.

Use of the product should be in accordance with official, national and regional antimicrobial policies.

Treatment with ketoconazole suppresses testosterone concentrations and increases progesterone concentrations and may affect breeding effectiveness in male dogs during and for some weeks after treatment.

Treatment of dermatophytosis should not be limited to treatment of the infected animal(s). It should also include disinfection of the environment, since spores can survive in the environment for long periods of time. Other measures such as frequent vacuuming, disinfection of grooming equipment and removal of all potentially contaminated material that cannot be disinfected will minimize the risk of re-infection or spread of infection.

Combination of systemic and topical treatment is recommended.

In case of long term treatment administration, liver function should be closely monitored. If clinical signs suggestive of liver dysfunction develop, treatment should be discontinued immediately. As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental ingestion should be avoided. Keep the blister in the outer carton to prevent access by children. Part (half/quarter) tablets should be stored in the original blister and be used for the next administration. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to ketoconazole should avoid contact with the veterinary medicinal product. Wash hands after use.

#### Special precautions for the protection of the environment:

Not applicable.

#### Other precautions:

Dermatophytes mentioned in the indication have zoonotic potential with risk of transmission to humans. Maintain good personal hygiene (washing hands after

handling the animal and avoiding direct contact with animal). If signs of skin lesions occur, contact your physician.

### 3.6 Adverse events

Dogs:

Rare (1 to 10 animals / 10,000 animals treated):	Neurological signs <sup>a</sup> (e.g. Ataxia, Tremor) Apathy <sup>a</sup> , Anorexia <sup>a</sup> Hepatic toxicosis <sup>a</sup> Vomiting <sup>a</sup> , Diarrhoea <sup>a</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Endocrine system disorder (anti-androgenic effects <sup>b,c</sup> , anti-glucocorticoid effects <sup>b</sup> )

<sup>a</sup> May be observed at standard doses.

<sup>b</sup>Transient. Ketoconazole inhibits the conversion of cholesterol to steroid hormones such as testosterone and cortisol in a dose dependent and time-dependent manner.

<sup>c</sup> See also section *Special precautions for safe use in the target species* for effects in male breeding dogs.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

#### Pregnancy:

The use is not recommended during pregnancy.

Studies in laboratory animals have shown evidence of teratogenic and embryotoxic effects.

### 3.8 Interaction with other medicinal products and other forms of interaction

Do not administer with antacids and/or H<sub>2</sub>-receptor antagonists (cimetidine/rantidine) or proton pump inhibitors (e.g. omeprazole) as the absorption of ketoconazole may be modified (absorption requires an acid environment).

Ketoconazole is a substrate and potent inhibitor of cytochrome P450 3A4 (CYP3A4). It may decrease the elimination of drugs metabolized by CYP3A4, thereby altering their plasma concentrations. This may result in increased plasma concentrations of e.g. cyclosporine, macrocyclic lactones (ivermectin, selamectin, milbemycin), midazolam, cisapride, calcium-channel blocking agents, fentanyl, digoxin, macrolides, methylprednisolone or coumarine anticoagulants. The increased plasma levels of drugs mentioned above can prolong the duration of effects as well as side effects.

On the other hand, inducers of cytochrome P450 may increase the rate of metabolism of ketoconazole, e.g. barbiturates or phenytoin can increase the rate of metabolism of ketoconazole, resulting in a decreased bioavailability, hence a decreased efficacy.

Ketoconazole may decrease theophylline serum concentrations.

Ketoconazole inhibits the conversion of cholesterol to cortisol and may thus affect trilostane / mitotane dosing in dogs concurrently being treated for hyperadrenocorticism.

It is not known to what extent these interactions are relevant for dogs and cats, but in the absence of data, co-administration of the veterinary medicinal product and these drugs should be avoided.

### 3.9 Administration routes and dosage

Oral use.

10 mg of ketoconazole per kg body weight daily, by oral administration. This corresponds to 1 tablet per 40 kg body weight daily.


It is recommended to sample the animal once a month during treatment and to stop antifungal administration after two negative cultures. When mycological follow up is not possible, treatment should be continued for an adequate period of time to ensure mycological cure. If lesions persist after 8 weeks of treatment, medication should be re-evaluated by the responsible veterinarian.

To be administered preferably together with food, in order to maximise absorption.

Tablets can be divided into halves or quarters to ensure accurate dosing. Put the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.

Halves: With the tip of the thumbs, exert a slight vertical pressure on both sides of the tablet to break it into halves.

Quarters: With the tip of a thumb, exert a slight vertical pressure on the middle of the tablet to break it into quarters.



To ensure a correct dosage, body weight should be determined as accurately as possible.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In cases of overdose the following effects may be seen: anorexia, vomiting, pruritus, alopecia and increase of hepatic alanine aminotransferase (ALT) and alkaline phosphatase (ALP).

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code:QJ02AB02**

### **4.2 Pharmacodynamics**

Ketoconazole is an antifungal agent with a wide spectrum, derived from imidazole-dioxolane, which exerts a fungistatic and sporicidal effect on dermatophytes in dogs.

Ketoconazole widely inhibits the cytochrome P450 system. Ketoconazole modifies the permeability of membranes of fungi, and inhibit specifically the synthesis of ergosterole, which is an essential component of the cellular membrane of fungi, principally by inhibiting the enzyme cytochrome P450 14-alpha-demethylase (P45014DM).

Ketoconazole has anti-androgen and anti-glucocorticoid effects; it inhibits the conversion of cholesterol to steroid hormones such as testosterone and cortisol. It produces this effect through inhibition of cytochrome P450 enzymes involved in the synthesis.

Through inhibition of CYP3A4, metabolism of many drugs is decreased and their *in-vivo* bioavailability increased.

Ketoconazole inhibits p-glycoprotein efflux pumps and may increase the oral absorption and tissue distribution of other medicines, e.g. prednisolone.

### **4.3 Pharmacokinetics**

After oral administration, peak plasma levels of 22 – 49 µg/ml (mean 35 µg/ml) are obtained within 1.5 to 4.0 hours (mean 2.9 hours).

Ketoconazole absorption is enhanced in an acidic environment and drugs that raise gastric pH may lessen absorption. High levels of the drug are found in the liver, adrenals, and pituitary gland, while more moderate levels are found in the kidneys, lungs, bladder, bone marrow, and myocardium. At usual doses (10 mg/kg), drug

levels attained are probably inadequate in the brain, testis, and eyes to treat most infections; higher dosages are required. It crosses the placenta (in rats) and is excreted into milk.

Ketoconazole is 84% - 99% bound to the albumin fraction of plasma proteins. Ketoconazole is metabolised by the liver into several inactive metabolites. It is excreted predominantly into bile and to a lesser extent into urine. The terminal elimination half-life ranged between 3 and 9 hours (mean 4.6 hours).

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life of divided tablets: 3 days.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **5.4 Nature and composition of immediate packaging**

Aluminium - PVC/PE/PVDC blister.  
Cardboard box of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 blisters, containing 10 tablets each.  
Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dechra Regulatory B.V.

## **7. MARKETING AUTHORISATION NUMBER**

Vm 50406/4028

## **8. DATE OF FIRST AUTHORISATION**

05 November 2014

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

December 2024

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*  
Approved 01 May 2025